Clinical, pathologic, and genetic features of breast implant–associated ALCLs
| Parameter . | No. positive/no. studied . | Percent positive . |
|---|---|---|
| Capsular infiltration (T3*) | 4/33 | 12 |
| Mass/infiltration beyond capsule (T4) | 10/33 | 30 |
| Lymph node involvement† | 4/30 | 13 |
| ALK (IHC‡) | 0/36 | 0 |
| DUSP22 rearrangement (FISH) | 0/36 | 0 |
| TP63 rearrangement (FISH) | 0/36 | 0 |
| pSTAT3Y705 (IHC) | 27/27 | 100 |
| JAK1 mutation (NGS) | 1/15 | 7§ |
| JAK3 mutation (NGS) | 0/15 | 0 |
| STAT3 mutation (NGS) | 3/15 | 20 |
| STAT5A mutation (NGS) | 0/15 | 0 |
| STAT5B mutation (NGS) | 0/15 | 0 |
| Parameter . | No. positive/no. studied . | Percent positive . |
|---|---|---|
| Capsular infiltration (T3*) | 4/33 | 12 |
| Mass/infiltration beyond capsule (T4) | 10/33 | 30 |
| Lymph node involvement† | 4/30 | 13 |
| ALK (IHC‡) | 0/36 | 0 |
| DUSP22 rearrangement (FISH) | 0/36 | 0 |
| TP63 rearrangement (FISH) | 0/36 | 0 |
| pSTAT3Y705 (IHC) | 27/27 | 100 |
| JAK1 mutation (NGS) | 1/15 | 7§ |
| JAK3 mutation (NGS) | 0/15 | 0 |
| STAT3 mutation (NGS) | 3/15 | 20 |
| STAT5A mutation (NGS) | 0/15 | 0 |
| STAT5B mutation (NGS) | 0/15 | 0 |
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing.
Based on the TNM staging system of Clemens et al.5 T staging data were not available in 3 patients. Clinical data on 17 cases were previously reported in Miranda et al.2
Extramammary staging data were not available in 6 patients; no spread to other organs/distant sites (M1) was identified in 30 evaluable patients.
Additional immunohistochemistry results are shown in supplemental Table 1.
Mutational frequencies are for mutations known or predicted to be activating.